Correspondence 0001193125-24-055978 from Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc.
Date: March 1, 2024 · CIK: 0001808898 · Accession: 0001193125-24-055978
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-277310
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Benitec Biopharma Inc. Registration Statement on Form S-3 (File No. 333-277310)
Dear Ms. Gama:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Benitec Biopharma Inc. hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-277310) so that it may become effective at 4:00 p.m. Eastern Time on March 5, 2024, or as soon thereafter as practicable.
Very truly yours,
BENITEC BIOPHARMA INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP BENITEC BIOPHARMA INC. 3940 TRUST WAY HAYWARD, CALIFORNIA 94545 March 1, 2024 VIA EDGAR Doris Stacey Gama Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Benitec Biopharma Inc. Registration Statement on Form S-3 (File No. 333-277310) Dear Ms. Gama: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Benitec Biopharma Inc. hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-277310) so that it may become effective at 4:00 p.m. Eastern Time on March 5, 2024, or as soon thereafter as practicable. Very truly yours, BENITEC BIOPHARMA INC. By: /s/ Dr. Jerel Banks Name: Dr. Jerel Banks Title: Chief Executive Officer cc: Louis Rambo, Proskauer Rose LLP